{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:04:32Z","timestamp":1792037072859,"version":"4.4.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022CF5T45"],"award-info":[{"award-number":["2022CF5T45"]}],"id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejmech.2026.118893","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:45:24Z","timestamp":1777045524000},"page":"118893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Recent advances in the development of selective hMAO-B inhibitors for neurodegenerative diseases: An update from 2020 to present"],"prefix":"10.1016","volume":"313","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6072-4698","authenticated-orcid":false,"given":"Silvia","family":"Salerno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Piazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Piccarducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Dalla Via","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8675-939X","authenticated-orcid":false,"given":"Sabrina","family":"Taliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Da Settimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118893_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2026.118893_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.yjmcc.2013.12.032","article-title":"Monoamine oxidases as sources of oxidants in the heart","volume":"73","author":"Kaludercic","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejmech.2026.118893_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-386467-3.00001-7","article-title":"Structural properties of human monoamine oxidases A and B","volume":"100","author":"Binda","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.ejmech.2026.118893_bib4","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00702-018-1915-z","article-title":"The structure of monoamine oxidases: past, present, and future","volume":"125","author":"Iacovino","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejmech.2026.118893_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.neuro.22.1.197","article-title":"Monoamine oxidase: from genes to behavior","volume":"22","author":"Shih","year":"1999","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2026.118893_bib6","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1073\/pnas.88.9.3637","article-title":"Human monoamine oxidase A and B genes exhibit identical exon-intron organization","volume":"88","author":"Grimsby","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118893_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2024.105831","article-title":"Monoamine oxidase and neurodegeneration: mechanisms, inhibitors and natural compounds for therapeutic intervention","volume":"179","author":"Banerjee","year":"2024","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2026.118893_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/265080a0","article-title":"Dopamine is a monoamine oxidase B substrate in man [33]","volume":"265","author":"Glover","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118893_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","article-title":"Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release","volume":"143","author":"Finberg","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118893_bib10","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/s41593-020-00735-y","article-title":"Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H2O2\u2212 production","volume":"23","author":"Chun","year":"2020","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2026.118893_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s13139-023-00837-y","article-title":"A key mediator and imaging target in alzheimer's disease: unlocking the role of reactive astrogliosis Through MAOB","volume":"58","author":"Nam","year":"2024","journal-title":"Nucl. Med. Mol. Imaging (2010)"},{"key":"10.1016\/j.ejmech.2026.118893_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-024-02712-2","article-title":"Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer's disease and related dementias","volume":"147","author":"Jaisa-aad","year":"2024","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejmech.2026.118893_bib13","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/brain\/awx172","article-title":"Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders","volume":"140","author":"Tong","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2026.118893_bib14","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00702-018-1881-5","article-title":"90 years of monoamine oxidase: some progress and some confusion","volume":"125","author":"Tipton","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejmech.2026.118893_bib15","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.3390\/ijms23084453","article-title":"Revisiting the role of astrocytic MAOB in Parkinson's disease","volume":"23","author":"Nam","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118893_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-017-0279-1","article-title":"Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with \u03b3-secretase and regulates neuronal amyloid \u03b2-peptide levels","volume":"9","author":"Schedin-Weiss","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejmech.2026.118893_bib17","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/brain\/awv405","article-title":"Inflammatory changes in very early Alzheimer's disease: friend, foe, or don't know?","volume":"139","author":"Schott","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2026.118893_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cotox.2018.12.002","article-title":"Biogenic aldehyde-mediated mechanisms of toxicity in neurodegenerative disease","volume":"13","author":"Cagle","year":"2019","journal-title":"Curr. Opin Toxicol."},{"key":"10.1016\/j.ejmech.2026.118893_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neulet.2015.01.064","article-title":"The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein","volume":"590","author":"Jinsmaa","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2026.118893_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.autneu.2015.12.008","article-title":"DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells, Auton","volume":"194","author":"Jinsmaa","year":"2016","journal-title":"Neurosci. Basic Clin."},{"key":"10.1016\/j.ejmech.2026.118893_bib21","doi-asserted-by":"crossref","first-page":"26978","DOI":"10.1074\/jbc.M111.249532","article-title":"Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone","volume":"286","author":"Anderson","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102667","article-title":"Oxidative stress and mitochondrial impairment: key drivers in neurodegenerative disorders","volume":"104","author":"Wen","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118893_bib23","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/401264","article-title":"Oxidative stress and microglial cells in Parkinson's disease","volume":"2012","author":"Peterson","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejmech.2026.118893_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.815347","article-title":"Microglia polarization From M1 to M2 in neurodegenerative diseases","volume":"14","author":"Guo","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2026.118893_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001616","article-title":"MAO-B elevation in Mouse brain astrocytes results in Parkinson's pathology","volume":"3","author":"Mallajosyula","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118893_bib26","first-page":"3724","article-title":"Role of monoamine oxidase activity in Alzheimer's disease: an insight into the therapeutic potential of inhibitors","volume":"26","author":"Behl","year":"2021","journal-title":"Molbank"},{"key":"10.1016\/j.ejmech.2026.118893_bib27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/brain\/awv404","article-title":"Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease","volume":"139","author":"Rodriguez-Vieitez","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2026.118893_bib28","first-page":"1276","article-title":"Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors","volume":"2","author":"Guglielmotto","year":"2010","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2026.118893_bib29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jnen\/60.8.759","article-title":"Oxidative damage is the earliest event in Alzheimer disease","volume":"60","author":"Nunomura","year":"2001","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ejmech.2026.118893_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111529","article-title":"Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer's disease by suppressing NLRP2 activation in astrocytes","volume":"542","author":"Zhang","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.118893_bib31","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s12276-021-00646-3","article-title":"Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis","volume":"53","author":"Cho","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.118893_bib32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.semcdb.2021.01.005","article-title":"GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and Alzheimer's disease","volume":"116","author":"Jim\u00e9nez-Balado","year":"2021","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2026.118893_bib33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cmet.2022.05.011","article-title":"Astrocytic urea cycle detoxifies A\u03b2-derived ammonia while impairing memory in Alzheimer's disease","volume":"34","author":"Ju","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2026.118893_bib34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JPD-212976","article-title":"Monoamine Oxidase-B inhibitors for the treatment of Parkinson's disease: past, present, and future","volume":"12","author":"Tan","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ejmech.2026.118893_bib35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev-neuro-100720-034518","article-title":"Parkinson's disease genetics and pathophysiology","volume":"44","author":"V\u00e1zquez-V\u00e9lez","year":"2021","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2026.118893_bib36","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.22971","article-title":"Incidental lewy body disease: clinical comparison to a control cohort","volume":"25","author":"Adler","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejmech.2026.118893_bib37","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118893_bib38","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in \u03b1-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118893_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2025.102798","article-title":"Beyond neurons: how does dopamine signaling impact astrocytic functions and pathophysiology?","volume":"251","author":"Favetta","year":"2025","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2026.118893_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1375265","article-title":"Non-motor symptoms associated with progressive loss of dopaminergic neurons in a mouse model of Parkinson's disease","volume":"18","author":"Radlicka-Borysewska","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2026.118893_bib41","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2026.118893_bib42","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1007\/s12035-020-02073-3","article-title":"Gut Microbiota and dysbiosis in Alzheimer's disease: implications for pathogenesis and treatment","volume":"57","author":"Liu","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2026.118893_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.676239","article-title":"Monoamine oxidase inhibitors: a review of Their anti-inflammatory therapeutic potential and mechanisms of action","volume":"12","author":"Ostadkarampour","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118893_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1004215","article-title":"A monoamine oxidase B inhibitor ethyl ferulate suppresses microglia-mediated neuroinflammation and alleviates ischemic brain injury","volume":"13","author":"Zou","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118893_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103393","article-title":"Monoamine oxidases: a missing link between mitochondria and inflammation in chronic diseases","volume":"77","author":"Beucher","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejmech.2026.118893_bib46","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s11030-023-10634-6","article-title":"Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach","volume":"28","author":"Baweja","year":"2024","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2026.118893_bib47","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.14336\/AD.2020.1225","article-title":"An update on medical and surgical treatments of parkinson's disease","volume":"12","author":"Nemade","year":"2021","journal-title":"Aging Dis"},{"key":"10.1016\/j.ejmech.2026.118893_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40263-017-0408-1","article-title":"Safinamide: a review in Parkinson's disease","volume":"31","author":"Blair","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2026.118893_bib49","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/bdd.1822","article-title":"Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects","volume":"33","author":"Kr\u00f6sser","year":"2012","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.ejmech.2026.118893_bib50","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.3390\/molecules27134297","article-title":"Natural products inhibitors of monoamine Oxidases\u2014Potential new drug leads for neuroprotection, neurological disorders, and neuroblastoma","volume":"27","author":"Chaurasiya","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118893_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543776.2018.1427735","article-title":"MAO inhibitors and their wider applications: a patent review","volume":"28","author":"Carradori","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118893_bib52","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/slct.202004188","article-title":"An update of synthetic approaches and structure-activity relationships of various classes of human MAO-B inhibitors","volume":"6","author":"Sharma","year":"2021","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ejmech.2026.118893_bib53","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/med.21561","article-title":"Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: an overview and update","volume":"39","author":"Tripathi","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118893_bib54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/1871524919666190131160122","article-title":"Unraveling the structural requirements of chalcone chemistry Towards monoamine oxidase inhibition","volume":"19","author":"Mathew","year":"2019","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib55","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1871524915666151002124443","article-title":"Monoamine oxidase inhibitory action of chalcones: a mini review","volume":"16","author":"Mathew","year":"2015","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib56","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2174\/1568026615666150427113103","article-title":"Coumarins: auspicious cholinesterase and monoamine oxidase inhibitors","volume":"15","author":"Orhan","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib57","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/1386207320666170227155517","article-title":"Structural exploration of synthetic chromones as selective MAO-B inhibitors: a mini review","volume":"20","author":"Mathew","year":"2017","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.1016\/j.ejmech.2026.118893_bib58","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/1871524915666150831141705","article-title":"Opening new scenarios for human MAO inhibitors","volume":"16","author":"De Monte","year":"2016","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib59","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1021\/jm801590u","article-title":"Chalcones: a valid scaffold for monoamine oxidases inhibitors","volume":"52","author":"Chimenti","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib60","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DDDT.S236586","article-title":"Reversible small molecule inhibitors of MAO A and MAO B with anilide motifs","volume":"14","author":"Hagenow","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2026.118893_bib61","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/jphp.13264","article-title":"Design of enamides as new selective monoamine oxidase-B inhibitors","volume":"72","author":"Kavully","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118893_bib62","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.3390\/molecules28124814","article-title":"Structure-Based design of novel MAO-B inhibitors: a review","volume":"28","author":"Mateev","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118893_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112650","article-title":"Chalcones: unearthing their therapeutic possibility as monoamine oxidase B inhibitors","volume":"205","author":"Guglielmi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103335","article-title":"Design, synthesis and biological evaluation of oxygenated chalcones as potent and selective MAO-B inhibitors","volume":"93","author":"Parambi","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib67","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1080\/14756366.2020.1797711","article-title":"Design, synthesis, and evaluation of 1, 4-benzodioxan-substituted chalcones as selective and reversible inhibitors of human monoamine oxidase B","volume":"35","author":"Kong","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib68","first-page":"1","article-title":"1, 4-benzodioxan-substituted thienyl chalcone derivatives as novel reversible inhibitors of human monoamine oxidase B with anti-neuroinflammatory activity","volume":"15","author":"Sun","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118893_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117990","article-title":"Design, synthesis, and biological evaluation of chalcone derivatives as selective Monoamine Oxidase-B inhibitors with potential neuroprotective effects","volume":"298","author":"Facchetti","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib70","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1021\/acsmedchemlett.1c00238","article-title":"Promising non-cytotoxic monosubstituted chalcones to target monoamine Oxidase-B","volume":"12","author":"Iacovino","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118893_bib73","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/cbdd.14238","article-title":"Exploration of a new class of monoamine oxidase B inhibitors by assembling benzyloxy pharmacophore on halogenated chalcones","volume":"102","author":"Singh","year":"2023","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2026.118893_bib74","first-page":"1","article-title":"Development of morpholine ring-bearing halogenated \u03b1,\u03b2-unsaturated ketones as selective monoamine oxidase-B inhibitors","volume":"67","author":"Lee","year":"2024","journal-title":"Appl. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib75","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3390\/ph14111148","article-title":"Replacement of chalcone-ethers with chalcone-thioethers as potent and highly selective monoamine oxidase-b inhibitors and their protein-ligand interactions","volume":"14","author":"Mathew","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.118893_bib76","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1021\/acsomega.2c07694","article-title":"Development of isopropyl-tailed chalcones as a new class of selective MAO-B inhibitors for the treatment of Parkinson's disorder","volume":"8","author":"Kumar","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118893_bib80","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.4c00246","article-title":"Exploring the 1-(4-Nitrophenyl)-3-arylprop-2-en-1-one scaffold for the selective inhibition of monoamine oxidase B","author":"Meleddu","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118893_bib128","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1080\/07391102.2020.1796803","article-title":"Revealing the role of fluorine pharmacophore in chalcone scaffold for shifting the MAO-B selectivity: investigation of a detailed molecular dynamics and quantum chemical study","volume":"39","author":"Olotu","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2026.118893_bib63","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/13543776.2019.1613374","article-title":"An updated patent review of therapeutic applications of chalcone derivatives (2014-present)","volume":"29","author":"Kar Mahapatra","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118893_bib64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bioorg.2018.06.009","article-title":"Multi-targetable chalcone analogs to treat deadly Alzheimer's disease: current view and upcoming advice","volume":"80","author":"Zhang","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib82","doi-asserted-by":"crossref","first-page":"8184","DOI":"10.1021\/acsomega.2c00397","article-title":"Conjugated dienones from differently substituted cinnamaldehyde as highly potent monoamine Oxidase-B inhibitors: synthesis, biochemistry, and computational chemistry","volume":"7","author":"Mathew","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118893_bib83","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1039\/D4MD00608A","article-title":"Inhibition of monoamine oxidases by heterocyclic derived conjugated dienones: synthesis and in vitro and in silico investigations","volume":"16","author":"Kumar","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib85","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3390\/ph16091310","article-title":"A concise review of the recent structural explorations of chromones as MAO-B inhibitors: update from 2017 to 2023","volume":"16","author":"Ipe","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.118893_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116255","article-title":"Synthesis and biological evaluation of 3-styrylchromone derivatives as selective monoamine oxidase B inhibitors","volume":"42","author":"Takao","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib89","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11696-020-01332-w","article-title":"Design and synthesis of novel benzyloxy-tethered-chromone-carboxamide derivatives as potent and selective human monoamine oxidase-b inhibitors","volume":"75","author":"Rao","year":"2021","journal-title":"Chem. Pap."},{"key":"10.1016\/j.ejmech.2026.118893_bib90","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1248\/cpb.c20-00579","article-title":"Syntheses and evaluation of 2- or 3-(N-Cyclicamino)chromone derivatives as monoamine oxidase inhibitors","volume":"68","author":"Takao","year":"2020","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2026.118893_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114507","article-title":"Design and synthesis of chromone-based monoamine oxidase B inhibitors with improved drug-like properties","volume":"239","author":"Reis","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-26929-x","article-title":"Introduction of benzyloxy pharmacophore into aryl\/heteroaryl chalcone motifs as a new class of monoamine oxidase B inhibitors","volume":"12","author":"Sudevan","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118893_bib72","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejmech.2017.04.055","article-title":"The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase","volume":"135","author":"Mostert","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib77","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/14756366.2016.1247061","article-title":"Through scaffold modification to 3,5-diaryl-4,5-dihydroisoxazoles: new potent and selective inhibitors of monoamine oxidase B","volume":"32","author":"Meleddu","year":"2017","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib78","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ejmech.2015.12.026","article-title":"Drug design, synthesis, in vitro and in silico evaluation of selective monoaminoxidase B inhibitors based on 3-acetyl-2-dichlorophenyl-5-aryl-2,3-dihydro-1,3,4-oxadiazole chemical scaffold","volume":"108","author":"Distinto","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib79","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1021\/jm2002876","article-title":"3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: a new scaffold for the selective inhibition of monoamine oxidase B","volume":"54","author":"Maccioni","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejmech.2012.11.006","article-title":"1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors","volume":"59","author":"Desideri","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib84","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/cmdc.201600359","article-title":"Chromones: a promising ring system for new anti-inflammatory drugs","volume":"11","author":"Silva","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.118893_bib86","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1016\/j.bmcl.2012.07.025","article-title":"Selected chromone derivatives as inhibitors of monoamine oxidase","volume":"22","author":"Legoabe","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118893_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103285","article-title":"2-Styrylchromone derivatives as potent and selective monoamine oxidase B inhibitors","volume":"92","author":"Takao","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib92","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1021\/acs.jmedchem.6b00527","article-title":"Discovery of new chemical entities for old targets: insights on the lead optimization of chromone-based monoamine oxidase B (MAO-B) inhibitors","volume":"59","author":"Reis","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib93","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1021\/acs.jmedchem.7b00918","article-title":"Coumarin versus chromone monoamine oxidase B inhibitors: quo vadis?","volume":"60","author":"Fonseca","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib94","first-page":"262","article-title":"Coumarin derivatives as inhibitors against monoamine oxidase: structure-activity relationships and inhibitory mechanisms","volume":"4","author":"Sun","year":"2025","journal-title":"Acta Mater. Medica"},{"issue":"36","key":"10.1016\/j.ejmech.2026.118893_bib95","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40880-017-0217-4","article-title":"Cancer chemoprevention through dietary flavonoids: what's limiting?","volume":"361","author":"Amawi","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118893_bib96","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1021\/acs.jnatprod.6b00440","article-title":"Isolation of acacetin from Calea urticifolia with inhibitory properties against human monoamine Oxidase-A and -B","volume":"79","author":"Chaurasiya","year":"2016","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2026.118893_bib97","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.phytol.2019.04.021","article-title":"Acacetin\u2014A simple flavone exhibiting diverse pharmacological activities","volume":"32","author":"Semwal","year":"2019","journal-title":"Phytochem. Lett."},{"key":"10.1016\/j.ejmech.2026.118893_bib98","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jep.2008.02.015","article-title":"Isolation of the MAO-inhibitor naringenin from Mentha aquatica L","volume":"117","author":"Olsen","year":"2008","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2026.118893_bib99","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phymed.2017.12.032","article-title":"Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants","volume":"40","author":"Larit","year":"2018","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2026.118893_bib100","doi-asserted-by":"crossref","first-page":"10719","DOI":"10.1021\/acs.jafc.0c04502","article-title":"Luteolin, a potent human monoamine Oxidase-A inhibitor and dopamine D4 and vasopressin V1A receptor antagonist","volume":"68","author":"Park","year":"2020","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib101","first-page":"810","article-title":"Selective inhibition of human monoamine oxidase B by acacetin 7-Methyl ether isolated from Turnera diffusa (Damiana)","volume":"24","author":"Chaurasiya","year":"2019","journal-title":"Molbank"},{"key":"10.1016\/j.ejmech.2026.118893_bib102","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1021\/acs.jafc.6b03529","article-title":"Inhibition of human monoamine oxidase: biological and molecular modeling studies on selected natural flavonoids","volume":"64","author":"Carradori","year":"2016","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib103","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/biomedicines9101304","article-title":"Computationally assisted lead optimization of novel potent and selective mao-b inhibitors","volume":"9","author":"Gogineni","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.118893_bib104","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1021\/acsmedchemlett.3c00573","article-title":"Synthesis and monoamine oxidase inhibitory activity of halogenated flavones","volume":"15","author":"Castillo-Arellano","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118893_bib107","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/cbdd.13919","article-title":"Deciphering the detailed structure\u2013activity relationship of coumarins as Monoamine oxidase enzyme inhibitors\u2014An updated review","volume":"98","author":"Koyiparambath","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2026.118893_bib105","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/cmdc.202000018","article-title":"Coumarin-Rasagiline hybrids as potent and selective hMAO-B inhibitors, antioxidants, and neuroprotective agents","volume":"15","author":"Matos","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.118893_bib106","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/0929867327666200121165931","article-title":"New aspects of monoamine oxidase B inhibitors: the key role of halogens to open the golden door","volume":"28","author":"Mathew","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib108","doi-asserted-by":"crossref","first-page":"16244","DOI":"10.1021\/acsomega.2c01470","article-title":"Exploration of the detailed structure\u2212activity relationships of Isatin and their isomers as monoamine oxidase inhibitors","volume":"7","author":"Kumar","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118893_bib109","doi-asserted-by":"crossref","first-page":"35240","DOI":"10.1039\/D3RA07035B","article-title":"Isatin-based benzyloxybenzene derivatives as monoamine oxidase inhibitors with neuroprotective effect targeting neurogenerative disease treatment","volume":"13","author":"Benny","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.118893_bib110","first-page":"122","article-title":"Synthesis and biological activities of benzothiazole derivatives: a review","volume":"1","author":"Yadav","year":"2023","journal-title":"Int. Pharmacop."},{"key":"10.1016\/j.ejmech.2026.118893_bib111","first-page":"1086","article-title":"A mini-review on pharmacological importance of Benzothiazole Scaffold, mini. Rev","volume":"18","author":"Asif","year":"2021","journal-title":"Org. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib112","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3109\/14756366.2016.1161621","article-title":"Synthesis of some novel 2-substituted benzothiazole derivatives containing benzylamine moiety as monoamine oxidase inhibitory agents","volume":"31","author":"Kaya","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116266","article-title":"Novel 6-hydroxybenzothiazol-2-carboxamides as potent and selective monoamine oxidase B inhibitors endowed with neuroprotective activity","volume":"269","author":"Al-Saad","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib115","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s00044-024-03283-3","article-title":"Synthesis and evaluation of 2-methylbenzothiazole derivatives as monoamine oxidase inhibitors","volume":"33","author":"Shaw","year":"2024","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.118893_bib116","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00044-023-03042-w","article-title":"Investigation of the monoamine oxidase inhibition properties of benzoxathiolone derivatives","volume":"32","author":"Prinsloo","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.118893_bib114","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1021\/jm070677y","article-title":"Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs","volume":"50","author":"Binda","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib117","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejmech.2018.01.031","article-title":"Design, synthesis and in vitro biological evaluation of novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives containing a thiosemicarbazide moiety","volume":"146","author":"Geng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib118","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejmech.2017.12.013","article-title":"Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors","volume":"144","author":"Can","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib119","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s43440-020-00070-w","article-title":"Synthesis, molecular modelling and biological activity of some pyridazinone derivatives as selective human monoamine oxidase-B inhibitors","volume":"72","author":"\u00d6zdemir","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2026.118893_bib120","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.3390\/molecules25225371","article-title":"Design, synthesis, and biological evaluation of pyridazinones containing the (2-Fluorophenyl) piperazine moiety as selective MAO-B inhibitors","volume":"25","author":"\u00c7e\u00e7en","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118893_bib121","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.3390\/molecules27123801","article-title":"Development of a novel class of pyridazinone derivatives as selective MAO-B inhibitors","volume":"27","author":"Alag\u00f6z","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118893_bib122","doi-asserted-by":"crossref","first-page":"15021","DOI":"10.1021\/acs.jmedchem.0c01663","article-title":"Computational fragment-based design facilitates discovery of potent and selective monoamine Oxidase-B (MAO-B) inhibitor","volume":"63","author":"Jin","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128748","article-title":"Discovery of 3, 6-disubstituted isobenzofuran-1(3H)-ones as novel inhibitors of monoamine oxidases","volume":"67","author":"Liu","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118893_bib123","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.bmcl.2013.01.003","article-title":"Inhibition of monoamine oxidase by phthalide analogues","volume":"23","author":"Strydom","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118893_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105623","article-title":"6-Benzyloxyphthalides as selective and reversible monoamine oxidase B inhibitors with antioxidant and anti-neuroinflammatory activities for Parkinson's disease treatment","volume":"120","author":"Song","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114025","article-title":"Enhancing monoamine oxidase B inhibitory activity via chiral fluorination: Structure-activity relationship, biological evaluation, and molecular docking study","volume":"228","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107877","article-title":"Development of novel aza-stilbenes as a new class of selective MAO-B inhibitors for the treatment of Parkinson's disease","volume":"153","author":"Knez","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115956","article-title":"Discovery of C-3 isoxazole substituted thiochromone S,S-dioxide derivatives as potent and selective inhibitors for monoamine oxidase B (MAO-B)","volume":"263","author":"Mi","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib130","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1021\/acs.jmedchem.8b00357","article-title":"Tight-Binding inhibition of human monoamine oxidase B by chromone analogs: a kinetic, crystallographic, and biological analysis","volume":"61","author":"Reis","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib132","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1073\/pnas.0710626105","article-title":"Structure of human monoamine oxidase A at 2.2-\u00c5 resolution: the control of opening the entry for substrates\/inhibitors","volume":"105","author":"Son","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118893_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108940","article-title":"Discovery of C-3 nitrothiophene substituted thiochromone derivatives as potent and selective human monoamine oxidase B (hMAO-B) inhibitors for the treatment of atherosclerosis","volume":"165","author":"Lin","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126677","article-title":"1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B","volume":"29","author":"Shetnev","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118893_bib135","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00044-024-03346-5","article-title":"Monoamine oxidase inhibition by thiazole derivatives substituted with the benzenesulfonamide moiety","volume":"34","author":"Shetnev","year":"2024","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.118893_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128994","article-title":"Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors","volume":"76","author":"Jadoon","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118893_bib144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-024-82771-3","article-title":"New class of thio\/semicarbazide-based benzyloxy derivatives as selective class of monoamine oxidase-B inhibitors","volume":"14","author":"Chandran","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118893_bib136","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s10517-025-06480-1","article-title":"Antiparkinsonian activity of benzenesulfonamide derivatives, selective MAO-B inhibitors","volume":"179","author":"Khokhlov","year":"2025","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.118893_bib137","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1016\/j.bmcl.2010.06.128","article-title":"Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening","volume":"20","author":"Geldenhuys","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118893_bib138","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/138945012799499794","article-title":"Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for alzheimers disease treatment","volume":"13","author":"Weinreb","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2026.118893_bib139","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejmech.2011.12.027","article-title":"Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B","volume":"48","author":"Distinto","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib141","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/13102818.2022.2098819","article-title":"Design, synthesis and evaluation of semi- and thiosemicarbazides containing a methylxanthine moiety with in vitro neuroprotective and MAO-B inhibitory activities","volume":"36","author":"Mitkov","year":"2022","journal-title":"Biotechnol. Biotechnol. Equip."},{"key":"10.1016\/j.ejmech.2026.118893_bib142","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1080\/07391102.2020.1782266","article-title":"Development of methylthiosemicarbazones as new reversible monoamine oxidase-B inhibitors for the treatment of Parkinson's disease","volume":"39","author":"Mathew","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2026.118893_bib143","first-page":"38","article-title":"A therapeutic journey of semicarbazide and thio semicarbazide derivatives and their transition metals complexes: mini review","volume":"7","author":"BA","year":"2018","journal-title":"Res. Rev. J. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib145","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1016\/j.bmcl.2013.06.049","article-title":"Discovery, synthesis, and structure\u2013activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators","volume":"23","author":"Kubas","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118893_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117580","article-title":"2-(Phenylamino)-7,8-dihydroquinazolin-5(6H)-one, a promising scaffold for MAO-B inhibitors with potential GSK3\u03b2 targeting","volume":"291","author":"Di Paolo","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117983","article-title":"Design, synthesis, and biological activity of 2-aroylbenzofuran-3-ols and 2-aroylbenzofuran derivatives: a new route towards hMAO-B inhibition","volume":"297","author":"Guglielmi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib147","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1080\/14756366.2019.1653864","article-title":"Benzo[b]tiophen-3-ol derivatives as effective inhibitors of human monoamine oxidase: design, synthesis, and biological activity","volume":"34","author":"Guglielmi","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118893_bib149","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.7150\/thno.83066","article-title":"New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs)","volume":"13","author":"Palanisamy","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.118893_bib150","doi-asserted-by":"crossref","DOI":"10.1002\/jex2.156","article-title":"Mesenchymal stem cell-derived extracellular vesicles: recent therapeutics and targeted drug delivery advances","volume":"3","author":"Bhat","year":"2024","journal-title":"J. Extracell. Biol."},{"key":"10.1016\/j.ejmech.2026.118893_bib151","article-title":"Mesenchymal stem cell-derived extracellular vesicles: current advances in preparation and therapeutic applications for neurological disorders","volume":"13","author":"Li","year":"2025","journal-title":"Front. Cell Dev. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:19:45Z","timestamp":1783131585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":150,"alternative-id":["S0223523426003387"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118893","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the development of selective hMAO-B inhibitors for neurodegenerative diseases: An update from 2020 to present","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118893"}}